Information date: 23 October 2026 — Under the cosmetics regulation in force since 2021 and its implementing rules, imported ordinary cosmetics are filed and special cosmetics are registered with NMPA before import. Filings require a responsible mainland entity, a full ingredient dossier, safety assessment and, for efficacy claims, substantiation; the animal-testing exemption is available for general cosmetics where specified safety and manufacturing conditions are met. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
Under the cosmetics regulation in force since 2021 and its implementing rules, imported ordinary cosmetics are filed and special cosmetics are registered with NMPA before import. Filings require a responsible mainland entity, a full ingredient dossier, safety assessment and, for efficacy claims, substantiation; the animal-testing exemption is available for general cosmetics where specified safety and manufacturing conditions are met.
Check the product's classification as ordinary or special, whether any ingredient is a new cosmetic ingredient requiring approval, whether the claim is a cosmetic claim or would be treated as medical, and whether the manufacturing site and product type meet the conditions for the animal-testing exemption. Confirm the responsible entity's obligations for adverse-event reporting and for keeping the filing dossier.
How the effect reaches operations
The regime shifts responsibility onto the filer: the responsible mainland entity must hold the safety assessment and ingredient data and be able to produce it on inspection, and efficacy claims must be backed by substantiation that matches the claim wording. The animal-testing exemption is conditional rather than automatic, and a product that fails a condition falls back into the testing requirement, which changes both cost and timeline.
Copying efficacy language from another market can create a claim that requires substantiation the brand does not hold, or that crosses into medical claims and triggers a different review. Assuming the animal-testing exemption always applies to imported general cosmetics is a frequent misjudgement, as is treating the filing as a one-off rather than an ongoing record-keeping obligation.
For “Review: China's Cosmetics Regulation in Practice — Ingredient Dossiers, Efficacy Claims and the Animal-Testing Exemption for Imported Brands”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
If the brand sells only general cosmetics with established ingredients, plan the filing route and verify the exemption conditions for each manufacturing site. If the product is special cosmetics, uses a new ingredient, or makes strong efficacy claims, budget for testing and substantiation up front. Where claims are central to marketing, have the Chinese wording reviewed before filing rather than after.
Implementation checklist
- Classify each SKU as ordinary or special before filing.
- Verify animal-testing exemption conditions per manufacturing site.
- Match efficacy claim wording to substantiation already held.
- Assign one decision owner, one implementation owner and a dated review point for “Review: China's Cosmetics Regulation in Practice — Ingredient Dossiers, Efficacy Claims and the Animal-Testing Exemption for Imported Brands”.
- For “Review: China's Cosmetics Regulation in Practice — Ingredient Dossiers, Efficacy Claims and the Animal-Testing Exemption for Imported Brands”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “Review: China's Cosmetics Regulation in Practice — Ingredient Dossiers, Efficacy Claims and the Animal-Testing Exemption for Imported Brands”.
Evidence and review
For “Review: China's Cosmetics Regulation in Practice — Ingredient Dossiers, Efficacy Claims and the Animal-Testing Exemption for Imported Brands”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Classify each SKU as ordinary or special before filing.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Verify animal-testing exemption conditions per manufacturing site.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Match efficacy claim wording to substantiation already held.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
This is a practice review based on published rules and does not constitute regulatory or legal advice; filing outcomes depend on the specific formula, claims and manufacturing arrangements.
